133 related articles for article (PubMed ID: 35996941)
1. Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes.
Makhnoon S; Chen M; Levin B; Ensinger M; Mattie KD; Grana G; Shete S; Arun BK; Peterson SK
Cancer; 2022 Oct; 128(20):3709-3717. PubMed ID: 35996941
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
3. Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.
Ro V; McGuinness JE; Guo B; Trivedi MS; Jones T; Chung WK; Rao R; Levinson E; Koval C; Russo D; Chilton I; Kukafka R; Crew KD
JCO Oncol Pract; 2022 Apr; 18(4):e472-e483. PubMed ID: 34705516
[TBL] [Abstract][Full Text] [Related]
4. Risk management decisions in women with BRCA1 and BRCA2 mutations.
Morgan R; Brown A; Hamman KJ; Sampson J; Naik A; Massimino K
Am J Surg; 2018 May; 215(5):899-903. PubMed ID: 29499861
[TBL] [Abstract][Full Text] [Related]
5. Differences among a Portuguese cohort of BRCA pathogenic/likely pathogenic variants carriers choosing risk-reducing mastectomy or intensive breast surveillance.
Torres S; Peleteiro B; Magalhães A; Garrido L; Costa S; Fougo JL
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7529-7538. PubMed ID: 36971799
[TBL] [Abstract][Full Text] [Related]
6. Influence of germline test results on surgical decision making in women with invasive breast cancer.
Vargason AB; Turner CE; Shriver CD; Ellsworth RE
Cancer Genet; 2022 Aug; 266-267():81-85. PubMed ID: 35868102
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
[TBL] [Abstract][Full Text] [Related]
8. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer surveillance in BRCA positive Sri Lankan women: health equity for a high-risk group at a limited resource setting.
Liyanage UA; Sirisena ND; Deshapriya PC; Dissanayake VHW
BMC Womens Health; 2023 Nov; 23(1):636. PubMed ID: 38017478
[TBL] [Abstract][Full Text] [Related]
10. Preconception carrier screening yield: effect of variants of unknown significance in partners of carriers with clinically significant variants.
Fridman H; Behar DM; Carmi S; Levy-Lahad E
Genet Med; 2020 Mar; 22(3):646-653. PubMed ID: 31624327
[TBL] [Abstract][Full Text] [Related]
11. Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.
Hegde JV; Wang X; Attai DJ; DiNome ML; Kusske A; Hoyt AC; Hurvitz SA; Weidhaas JB; Steinberg ML; McCloskey SA
Breast Cancer Res Treat; 2017 Nov; 166(1):145-156. PubMed ID: 28702891
[TBL] [Abstract][Full Text] [Related]
12. Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.
Makhnoon S; Bednar EM; Krause KJ; Peterson SK; Lopez-Olivo MA
Clin Genet; 2021 Aug; 100(2):119-131. PubMed ID: 33843052
[TBL] [Abstract][Full Text] [Related]
13. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
[TBL] [Abstract][Full Text] [Related]
14. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
Botkin JR; Smith KR; Croyle RT; Baty BJ; Wylie JE; Dutson D; Chan A; Hamann HA; Lerman C; McDonald J; Venne V; Ward JH; Lyon E
Am J Med Genet A; 2003 Apr; 118A(3):201-9. PubMed ID: 12673648
[TBL] [Abstract][Full Text] [Related]
15. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes.
Makhnoon S; Levin B; Ensinger M; Mattie K; Volk RJ; Zhao Z; Mendoza T; Shete S; Samiian L; Grana G; Grainger A; Arun B; Shirts BH; Peterson SK
Cancer Med; 2023 Feb; 12(3):2875-2884. PubMed ID: 36426404
[TBL] [Abstract][Full Text] [Related]
16. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
[TBL] [Abstract][Full Text] [Related]
18. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract][Full Text] [Related]
19. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
[TBL] [Abstract][Full Text] [Related]
20. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
